Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olanzapine
- Development stage
- Approved
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Olanzapine is a second-generation (atypical) antipsychotic medication primarily used to treat schizophrenia and bipolar I disorder in adults and adolescents. It is also indicated for the management of acute agitation associated with these disorders and can be used in combination with fluoxetine for treatment-resistant depression or depressive episodes in bipolar I disorder. Olanzapine acts mainly by antagonizing dopamine D2 and serotonin 5-HT2A receptors in the brain, which helps rebalance neurotransmitter activity to improve mood, thinking, and behavior. The drug is available as oral tablets (including orally disintegrating forms) and intramuscular injections[2][3][4][5].
- Brand names
- ZyprexaZyprexa ZydisZyprexa RelprevvZyprexa Intramuscular
- Other names
- olanzapine long-acting injectionOLAI
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on olanzapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olanzapine.